Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Solid Biosciences (SLDB) Gains from Sales and Divestitures (2018 - 2024)

Solid Biosciences (SLDB) has disclosed Gains from Sales and Divestitures for 5 consecutive years, with $237315.0 as the latest value for Q3 2024.

  • Quarterly Gains from Sales and Divestitures changed N/A to $237315.0 in Q3 2024 from the year-ago period, while the trailing twelve-month figure was $237315.0 through Sep 2024, changed N/A year-over-year, with the annual reading at $419193.0 for FY2021, 2.82% up from the prior year.
  • Gains from Sales and Divestitures hit $237315.0 in Q3 2024 for Solid Biosciences, up from $230536.0 in the prior quarter.
  • In the past five years, Gains from Sales and Divestitures ranged from a high of $419193.0 in Q4 2021 to a low of $230536.0 in Q2 2024.
  • Historically, Gains from Sales and Divestitures has averaged $323686.0 across 3 years, with a median of $322507.5 in 2020.
  • Biggest five-year swings in Gains from Sales and Divestitures: grew 20.55% in 2020 and later increased 2.82% in 2021.
  • Year by year, Gains from Sales and Divestitures stood at $407700.0 in 2020, then increased by 2.82% to $419193.0 in 2021, then crashed by 43.39% to $237315.0 in 2024.
  • Business Quant data shows Gains from Sales and Divestitures for SLDB at $237315.0 in Q3 2024, $230536.0 in Q2 2024, and $419193.0 in Q4 2021.